Omnicell (NASDAQ:OMCL) Releases FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 1.650-1.850 for the period, compared to the consensus EPS estimate of 1.780. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its Q1 2025 guidance to 0.150-0.250 EPS.

Analysts Set New Price Targets

OMCL has been the topic of several recent research reports. Bank of America lowered their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. JPMorgan Chase & Co. dropped their price objective on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, March 20th. Benchmark reissued a “buy” rating and issued a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a report on Monday. Finally, Wells Fargo & Company lowered their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $51.00.

Omnicell Trading Up 2.6 %

Shares of Omnicell stock opened at $35.35 on Friday. The stock has a 50 day moving average of $39.16 and a 200 day moving average of $42.64. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of 130.93, a PEG ratio of 7.53 and a beta of 0.85. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.75.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, research analysts predict that Omnicell will post 1.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.